ACRS earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -10.04. Updated 2026-07-23.
Aclaris Therapeutics (ACRS) Research Hub
Aclaris Therapeutics (ACRS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.79 USD (+1.07%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.04, market cap 0.67B. This hub links to the full technical, earnings and options research available for ACRS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.79 USD (+1.07%) |
| 52-week range | 3.18 USD – 6.6 USD |
| Trend regime | Range |
| 14-day RSI | 52.1 (Neutral) |
| Trailing P/E | -10.04 |
| Market cap | 0.67B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ACRS
Covered Call on ACRS: how it works, illustrative setup around the real 3.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACRS: how it works, illustrative setup around the real 3.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACRS: how it works, illustrative setup around the real 3.79 USD price, max profit/loss, breakeven and when to use it. Educational.
ACRS technical analysis: range, last 3.79 USD, RSI 52.1, 52w range 3.18 USD–6.6 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ACRS in?
Aclaris Therapeutics (ACRS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACRS in an uptrend or downtrend?
As of 2026-10-26, ACRS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACRS's trailing P/E ratio?
ACRS's trailing P/E is -10.04, with a market cap of 0.67B. See the earnings research page for full valuation detail.
When does ACRS next report earnings?
ACRS is next scheduled to report earnings on 2026-08-06.